Clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma

The Association for the Advancement of Blood and Biotherapies (AABB) has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma (CCP) in hospital and outpatient settings. Based on two living systematic reviews of randomized controlled trials (RCTs), the guidelines provide five specific recommendations for treating patients with COVID-19 and suggest that CCP is most effective when transfused with high neutralizing titers to infected patients early after symptom onset. The guidelines are published in Annals of Internal Medicine.